Nektar Therapeutics (NKTR) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NKTR Analyst Ratings

Strong Buy

8 Buy

1 Hold

0 Sell

Based on 9 analysts giving stock ratings to

Nektar

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NKTR Stock 12 Month Forecast

Average Price Target

$2,687.34

▲(118.48% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Nektar Therapeutics in the last 3 months. The average price target is $2,687.34 with a high forecast of $3,347.34 and a low forecast of $1,394.72. The average price target represents a 118.48% change from the last price of $1,230.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"164":"$164","960":"$960","1756":"$1,756","2552":"$2,552","3348":"$3,348"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3347.33869056,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$3.35K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2687.335154102857,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$2.69K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1394.7244544,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.39K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[164,960,1756,2552,3348],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1584.15,1719.7798992738462,1855.4097985476924,1991.0396978215385,2126.6695970953847,2262.299496369231,2397.929395643077,2533.559294916923,2669.1891941907693,2804.8190934646154,2940.4489927384616,3076.0788920123077,3211.708791286154,{"y":3347.33869056,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1584.15,1669.0103964694506,1753.870792938901,1838.7311894083516,1923.5915858778021,2008.4519823472526,2093.312378816703,2178.172775286154,2263.033171755604,2347.893568225055,2432.753964694505,2517.614361163956,2602.4747576334066,{"y":2687.335154102857,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1584.15,1569.5788041846154,1555.0076083692309,1540.4364125538461,1525.8652167384616,1511.294020923077,1496.7228251076924,1482.1516292923077,1467.5804334769232,1453.0092376615385,1438.438041846154,1423.8668460307692,1409.2956502153847,{"y":1394.7244544,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":165,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":414,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":543,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1135,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1030,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1030,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":693.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":693.5,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1319,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1584.15,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1584.15,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1584.15,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$3,347

Average Price Target$2,687

Lowest Price Target$1,395

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Edward Nash

Canaccord Genuity

$2,667.41

Buy

116.86%

Upside

Initiated

07/22/26

Nektar initiated with a Buy at CanaccordNektar initiated with a Buy at Canaccord

Samantha Semenkow

Citi

$2,632.54

Buy

114.03%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

Julian Harrison

BTIG

$3,103.26

Buy

152.30%

Upside

Reiterated

07/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Nektar Therapeutics (NASDAQ: NKTR) and Biogen (NASDAQ: BIIB)

Arthur He CFA

H.C. Wainwright

$3,225.3

Buy

162.22%

Upside

Reiterated

07/01/26

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS) and Nektar Therapeutics (NASDAQ: NKTR)

Martin Fan

Wedbush

$1,656.24→$1,394.72

Hold

13.39%

Upside

Reiterated

05/11/26

Nektar price target lowered to $80 from $95 at WedbushNektar price target lowered to $80 from $95 at Wedbush

Yasmeen Rahimi

Piper Sandler

$1,830.58→$3,347.34

Buy

172.14%

Upside

Reiterated

05/08/26

Nektar price target raised to $192 from $105 at Piper SandlerNektar price target raised to $192 from $105 at Piper Sandler

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

05/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay Olson

Oppenheimer

$2,440.77

Buy

98.44%

Upside

Reiterated

05/08/26

Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

05/07/26

Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating

Mayank Mamtani

B. Riley Securities

$1,830.58→$2,615.11

Buy

112.61%

Upside

Reiterated

02/23/26

Nektar price target raised to $150 from $105 at B. RileyNektar price target raised to $150 from $105 at B. Riley

Roger Song

Jefferies

$2,109.52

Buy

71.51%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)

Jessica Fye

J.P. Morgan

$523.02

Sell

-57.48%

Downside

Reiterated

11/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Edward Nash

Canaccord Genuity

$2,667.41

Buy

116.86%

Upside

Initiated

07/22/26

Nektar initiated with a Buy at CanaccordNektar initiated with a Buy at Canaccord

Samantha Semenkow

Citi

$2,632.54

Buy

114.03%

Upside

Reiterated

07/21/26

Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (NYSE: JNJ), Helus Pharma (NASDAQ: HELP) and Nektar Therapeutics (NASDAQ: NKTR)

Julian Harrison

BTIG

$3,103.26

Buy

152.30%

Upside

Reiterated

07/13/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Senseonics Holdings (NASDAQ: SENS), Nektar Therapeutics (NASDAQ: NKTR) and Biogen (NASDAQ: BIIB)

Arthur He CFA

H.C. Wainwright

$3,225.3

Buy

162.22%

Upside

Reiterated

07/01/26

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (NASDAQ: PYXS) and Nektar Therapeutics (NASDAQ: NKTR)

Martin Fan

Wedbush

$1,656.24→$1,394.72

Hold

13.39%

Upside

Reiterated

05/11/26

Nektar price target lowered to $80 from $95 at WedbushNektar price target lowered to $80 from $95 at Wedbush

Yasmeen Rahimi

Piper Sandler

$1,830.58→$3,347.34

Buy

172.14%

Upside

Reiterated

05/08/26

Nektar price target raised to $192 from $105 at Piper SandlerNektar price target raised to $192 from $105 at Piper Sandler

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

05/08/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Jay Olson

Oppenheimer

$2,440.77

Buy

98.44%

Upside

Reiterated

05/08/26

Oppenheimer Remains a Buy on Nektar Therapeutics (NKTR)

Andy Hsieh

William Blair

―

Buy

―

Reiterated

05/07/26

Nektar Therapeutics: Strong Cash Position and Late‑Stage Autoimmune Pipeline Underpin Attractive Risk‑Reward and Outperform Rating

Mayank Mamtani

B. Riley Securities

$1,830.58→$2,615.11

Buy

112.61%

Upside

Reiterated

02/23/26

Nektar price target raised to $150 from $105 at B. RileyNektar price target raised to $150 from $105 at B. Riley

Roger Song

Jefferies

$2,109.52

Buy

71.51%

Upside

Reiterated

12/17/25

Jefferies Sticks to Its Buy Rating for Nektar Therapeutics (NKTR)

Jessica Fye

J.P. Morgan

$523.02

Sell

-57.48%

Downside

Reiterated

11/09/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Zymeworks (NASDAQ: ZYME), Sana Biotechnology (NASDAQ: SANA) and Nektar Therapeutics (NASDAQ: NKTR)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

BBOTBridgeBio Oncology Therapeutics

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nektar Therapeutics

3 Months

Jessica FyeJ.P. Morgan

Success Rate

12/21 ratings generated profit

Average Return

+2.98%

Copying Jessica Fye's trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +2.98% per trade.

1 Year

Julian HarrisonBTIG

Success Rate

16/18 ratings generated profit

Average Return

+155.51%

Copying Julian Harrison's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +155.51% per trade.

2 Years

Julian HarrisonBTIG

Success Rate

16/18 ratings generated profit

Average Return

+168.18%

Copying Julian Harrison's trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +168.18% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NKTR Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NKTR has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. NKTR average Analyst price target in the past 3 months is 2,687.34.

Each month's total comprises the sum of three months' worth of ratings.

NKTR Financial Forecast

NKTR Earnings Forecast

Next quarter’s earnings estimate for NKTR is -$34.36 with a range of -$43.62 to -$27.37. The previous quarter’s EPS was -$31.73. NKTR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.76% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Sales Forecast

Next quarter’s sales forecast for NKTR is $181.75M with a range of $104.60M to $202.62M. The previous quarter’s sales results were $189.35M. NKTR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 48.79% of the time in the same period. In the last calendar year NKTR has Performed in-line its overall industry.

NKTR Stock Forecast FAQ

What is MX:NKTR’s average 12-month price target, according to analysts?

Based on analyst ratings, Nektar Therapeutics’s 12-month average price target is 2,687.34.

What is MX:NKTR’s upside potential, based on the analysts’ average price target?

Nektar Therapeutics has 118.48% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Nektar Therapeutics a Buy, Sell or Hold?

Nektar Therapeutics has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.

What is Nektar Therapeutics’s share price target?

The average share price target for Nektar Therapeutics is 2,687.34. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $3,347.34 ,and the lowest forecast is $1,394.72. The average share price target represents 118.48% Increase from the current price of $1,230.

What do analysts say about Nektar Therapeutics?

Nektar Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Nektar Therapeutics?

To buy shares of MX:NKTR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Nektar Therapeutics (NKTR) Stock Forecast & Price Target

NKTR Analyst Ratings

NKTR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nektar Therapeutics

NKTR Analyst Recommendation Trends

NKTR Financial Forecast

NKTR Earnings Forecast

NKTR Sales Forecast

NKTR Stock Forecast FAQ

Detailed List of Analyst Forecasts